The Trump administration’s revived rule to end rebates that drugmakers give to middlemen in Medicare is awaiting approval from the Office of Management and Budget and a final rule could be imminent, according to a person familiar with the matter.

The administration has said the rule would drive down the prices consumers pay for prescription drugs. An earlier version of the rule, a signature part of President Trump’s plan to lower drug prices, was withdrawn in 2019 because some White House advisers raised concerns that it could…

This post first appeared on wsj.com

You May Also Like

Tech’s Talent Wars Have Come Back to Bite It

When Stripe, a payments start-up valued at $74 billion, laid off more…

Vivek Ramaswamy resumes TV ad spending in Iowa after calling it ‘idiotic’

Vivek Ramaswamy’s presidential campaign will resume ad spending in Iowa this week,…

New public report to blame Saudi crown prince for 2018 killing of Jamal Khashoggi

The Biden administration will release an intelligence report Thursday that concludes that…

Trump co-defendant in Ga. case obtains subpoena for DA Fani Willis to testify about relationship with special prosecutor

Fulton County District Attorney Fani Willis and special prosecutor Nathan Wade have…